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What’s	the	best	drug	treatment	
for	premature	ejaculation?
antidepressants—specifically 
clomipramine, fluoxetine, paroxetine, 
and sertraline—are best and have been 
shown to improve symptoms of premature 
ejaculation (strength of recommendation 
[sor]: a, meta-analysis of randomized 
controlled trials [rcTs]). The topical 
application of prilocaine-lidocaine cream 
(trade name eMla) improves intravaginal 
ejaculatory latency time (IelT), but penile 
numbness and loss of erection may occur 
(sor: B, based on several small rcTs). 
 There is no evidence that 
phosphodiesterase type 5 (PDe5) 
inhibitors—such as sildenafil (viagra), 
vardenafil (levitra), and tadalafil 
(cialis)—decrease instances of premature 
ejaculation in otherwise healthy men. 
There is limited evidence, however, 
that PDe5 inhibitors reduce symptoms 
of premature ejaculation for men with 
concomitant erectile dysfunction  
(sor: B, systematic review of rcTs of 
variable quality).
overcome any reluctance 
to discuss premature ejaculation
Family physicians should be comfortable 
diagnosing and treating premature 
ejaculation because of their unique and 
long-term relationship with the patient. 
But that’s not always the case. Premature 
ejaculation is underdiagnosed and 
undertreated because of a reluctance to 
discuss it, by both patient and physician. 
 a thorough medical history, including 
pertinent sexual history and physical 
examination, can often establish the 
diagnosis of premature ejaculation. 
effective treatments can improve sexual 
satisfaction and quality of life for both the 
men and their partners. 
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z	Evidence	summary
Premature ejaculation is the most com-
mon male sexual dysfunction, but there 
is no universally accepted definition or 
validated screening instrument. The 
pathophysiology and etiology remain 
incompletely understood.1 Based on 
surveys, prevalence rates for premature 
ejaculation are approximately 20% to 
30%.1 
Studies in male rats have demon-
strated that serotonin with various 
5-HT receptor subtypes are involved in 
the ejaculatory process.2 Based on these 
studies, it’s been suggested that lifelong 
premature ejaculation is a neurobiolog-
ical phenomenon related to decreased 
central serotonergic neurotransmis-
sion, 5-HT2c receptor hyposensitivity, or 
5-HT1a receptor hypersensitivity.
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fast track
SSRIs significantly 
delay ejaculation 
compared with 
placebo
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Antidepressants		
delay	ejaculation
The introduction of selective serotonin 
reuptake inhibitors (SSRIs) revolution-
ized the treatment of premature ejacula-
tion.4 In 1994, the first study of SSRIs in 
men with premature ejaculation demon-
strated a delaying effect with paroxetine 
(Paxil).5 Since that time, SSRIs have been 
repeatedly investigated for their propensi-
ty to delay ejaculation. Certain SSRIs and 
the tricyclic antidepressant clomipramine 
(Anafranil) have become the agents of 
choice for the treatment of premature 
ejaculation.6 
A meta-analysis6 of 35 treatment 
studies with serotonergic antidepressants 
from 1943 to 2003 shows that, despite 
major differences in design and drug 
dosing, clomipramine, fluoxetine (Pro-
zac), paroxetine, and sertraline (Zoloft) 
significantly delay ejaculation compared 
with placebo. The percentage increase 
in IELT was the primary outcome mea-
sured. The rank order of efficacy was: 
1) paroxetine (1492% IELT in-
crease; 95% confidence interval [CI], 
918–2425) 
2) sertraline (790% IELT increase; 
95% CI, 532–1173)
3) clomipramine (512% IELT in-
crease; 95% CI, 234–1122) 
4) fluoxetine (295% IELT increase; 
95% CI, 172–506).6
Of the 35 studies used in the previ-
ous meta-analysis, 8 studies (N=263) 
were prospective, double-blind, real-time 
stopwatch studies that were separately 
analyzed in a subsequent meta-analysis. 
These 8 studies evaluated clomipramine, 
fluoxetine, paroxetine, sertraline, citalo-
pram (Celexa), fluvoxamine (Luvox), 
mirtazapine (Remeron), and nefazo-
done (Serzone) against placebo. Par-
oxetine (783% IELT increase, 95% CI, 
499–1228), clomipramine (360% IELT 
increase, 95% CI, 200–435), sertraline 
(313%, 95% CI, 161–608), and fluox-
etine (295%, 95% CI, 200–435) exerted 
a significant delay in the IELT compared 
with placebo.6
EMLA	cream:	“Improvement”		
and	“cure”	seen
EMLA cream, a topical anesthetic, has 
been evaluated as a treatment option 
for premature ejaculation. One double-
blinded RCT7 (N=29) showed signifi-
cant improvement in the IELT (mea-
sured by stopwatch by the subject’s 
partner) from baseline compared with 
placebo (8.45 min vs 1.95 min; P<.001) 
at 2 months. 
Another RCT8 (N=84) compared 
EMLA cream applied 15 minutes prior 
to intercourse, sildenafil 50 mg orally 
45 minutes prior to intercourse, EMLA 
cream plus sildenafil, and placebo. In the 
sildenafil-plus-EMLA group, 32% of the 
patients reported “improvement” and 
54% reported “cure,” which was defined 
as ejaculation delayed until the patient 
wished it. In the EMLA-only group, 27% 
of the patients reported “improvement” 
and 50% reported “cure.” This was a 
statistically significant difference when 
compared with the placebo and sildena-
fil-only groups (number needed to treat 
[NNT]=3). There was no significant dif-
ference in reports of “improvement” or 
“cure” between the placebo and sildena-
fil-only groups.
One small RCT9 (N=24) compared 
placebo with the application of EMLA 
cream 20, 30, and 45 minutes prior to 
sexual intercourse. Improvement was 
seen in IELT in the 20- and 30-minute 
group, but penile numbness and erection 
loss increased in the 30- and 45-minute 
group.
PDE5	inhibitors:		
No	convincing	evidence
A review10 of 14 clinical trials concluded 
that there is no convincing evidence for 
PDE5 inhibitors in the treatment of men 
with lifelong premature ejaculation and 
normal erectile function. One RCT11 
found no increase in IELT from baseline 
in men taking sildenafil when compared 
with placebo, although patients reported 
overall sexual satisfaction and confidence 
based on a questionnaire. 
Topical prilocaine/
lidocaine cream 
(EMLA) improves 
intravaginal  
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However, a study by Li et al12 treat-
ed 45 men with premature ejaculation 
and comorbid erectile dysfunction with 
sildenafil. Eighty-nine percent reported 
improved erectile function, and 60% re-
ported decreased severity of premature 
ejaculation.
Recommendations	from	others
The American Urological Association13 
recommends antidepressants as first-line 
systemic therapy for premature ejacula-
tion, specifically the SSRIs fluoxetine, 
paroxetine, sertraline, and the tricyclic 
clomipramine. Topical EMLA cream is 
also recommended, but the reduction of 
penile sensation may limit the accept-
ability of this treatment option.
The British Association for Sexual 
Health and HIV Special Interest Group 
for Sexual Dysfunction14 also recom-
mends SSRIs and clomipramine as they 
have the strongest evidence for their 
efficacy. The group emphasizes the im-
portance of combining behavioral and 
pharmacologic therapies as the manage-
ment approach should be tailored to the 
individual patient.  n
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